References
- Heim S, Billström R, Kristoffersson U, Mandahl N, Strömbeck B, Mitelman F. Variant Ph translocations in chronic myeloid leukemia. Cancer Genet Cytogenet 1985;18: 215–27.
- Richebourg S, Eclache V, Perot C, Portnoi MF, Van den Akker J, Terré C, . Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy. Cancer Genet Cytogenet 2008;182:95–102.
- Penserga ET, Skorski T. Fusion tyrosine kinases: A result and cause of genomic instability. Oncogene 2007;26:11–20.
- Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, . Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809–20.
- Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, . Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28–37.
- Mitelman F. ISCN: An international system for human cytogenetic nomenclature. Basel: S. Karger; 1995.
- Marin D, Khorashad JS, Foroni L, Milojkovic D, Szydlo R, Reid AG, . Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse? Br J Haematol 2009;145:373–5.
- Gorusu M, Benn P, Li Z, Fang M. On the genesis and prognosis of variant translocations in chronic myeloid leukemia. Cancer Genet Cytogenet 2007;173:97–106.
- El-Zimaity MM, Kantarjian H, Talpaz M, O’Brien S,Giles F, Garcia-Manero G, . Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol 2004; 125:187–95.